Clinical study on treatment of mild cognitive impairment by modified wuzi yanzong granule.
- Author:
Xue-mei WANG
1
;
Hong FU
;
Geng-xin LIU
Author Information
- Publication Type:Clinical Trial
- MeSH: Aged; Cognition Disorders; blood; drug therapy; DNA, Mitochondrial; blood; Double-Blind Method; Drugs, Chinese Herbal; therapeutic use; Female; Ginkgo biloba; Humans; Intelligence Tests; Male; Malondialdehyde; blood; Middle Aged; Phytotherapy; Superoxide Dismutase; blood
- From: Chinese Journal of Integrated Traditional and Western Medicine 2004;24(5):392-395
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the clinical efficacy and safety of modified Wuzi Yanzong Granule (MWYG) in treating mild cognitive impairment (MCI), and to explore its mechanism.
METHODSForty-four MCI patients were selected referring to the international recognized Peterson's criteria and randomly divided into two groups, the treated group treated with MWYG and the control group treated with Ginkgo leaf extraction, with the course of 3 months for both groups. Changes of memorial quotient (MQ), superoxide dismutase (SOD) activity, malondialdehyde (MDA) content, mitochondrial DNA (mtDNA) deletion rate and acetylcholinesterase (AchE) before and after treatment were observed.
RESULTSAfter treatment, levels of MQ, serum SOD activity increased and serum MDA content, mtDNA deletion rate and AchE decreased in both groups (P < 0.01), but the difference between the two groups was insignificant. No adverse reaction was found in two groups.
CONCLUSIONBoth MWYG and Ginkgo leaf capsule can effectively improve the memorial function of patients with MCI, the therapeutic mechanism is possibly related with the actions in reducing AchE activity, improving free radical metabolism, and alleviating mitochondrial DNA oxidation damage.
